Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial

DOI: 10.1186/s40880-019-0359-7

Keywords: Esophageal squamous cell carcinoma, Recurrent, Metastasis, Multicenter, open-label, randomized trial, Irinotecan, S-1, Overall survival, Progression-free survival, Objective response rate, Disease control rate

Full-Text   Cite this paper   Add to My Lib

Abstract:

The online version of this article (10.1186/s40880-019-0359-7) contains supplementary material, which is available to authorized users

Full-Text